HC Wainwright Reaffirms “Buy” Rating for Stoke Therapeutics (NASDAQ:STOK)

Stoke Therapeutics (NASDAQ:STOK)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research note issued on Wednesday,Benzinga reports. They presently have a $35.00 price objective on the stock. HC Wainwright’s price target points to a potential upside of 290.63% from the company’s previous close.

A number of other equities research analysts have also weighed in on the stock. Chardan Capital started coverage on shares of Stoke Therapeutics in a report on Friday, December 20th. They issued a “buy” rating and a $24.00 target price on the stock. Leerink Partnrs upgraded Stoke Therapeutics to a “strong-buy” rating in a report on Friday, October 11th. Leerink Partners assumed coverage on Stoke Therapeutics in a report on Monday, October 14th. They set an “outperform” rating and a $18.00 price target for the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Stoke Therapeutics in a report on Tuesday, December 10th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $22.00 target price on shares of Stoke Therapeutics in a report on Wednesday. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Stoke Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $21.29.

Stoke Therapeutics Stock Performance

Shares of NASDAQ:STOK opened at $8.96 on Wednesday. Stoke Therapeutics has a 52-week low of $4.09 and a 52-week high of $17.58. The business’s 50 day simple moving average is $11.98 and its two-hundred day simple moving average is $13.08. The firm has a market cap of $474.58 million, a P/E ratio of -4.27 and a beta of 0.95.

Stoke Therapeutics (NASDAQ:STOK) last issued its earnings results on Tuesday, November 5th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.05. The company had revenue of $4.89 million for the quarter, compared to analysts’ expectations of $3.46 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. On average, equities analysts forecast that Stoke Therapeutics will post -2.03 earnings per share for the current fiscal year.

Insider Buying and Selling at Stoke Therapeutics

In other news, insider Barry Ticho sold 13,945 shares of the company’s stock in a transaction on Friday, December 6th. The stock was sold at an average price of $12.78, for a total transaction of $178,217.10. Following the transaction, the insider now owns 47,332 shares of the company’s stock, valued at $604,902.96. This represents a 22.76 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, General Counsel Jonathan Allan sold 13,666 shares of the stock in a transaction on Monday, December 9th. The stock was sold at an average price of $13.61, for a total value of $185,994.26. Following the transaction, the general counsel now owns 21,476 shares of the company’s stock, valued at $292,288.36. The trade was a 38.89 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 62,849 shares of company stock worth $809,421 over the last three months. 11.30% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Stoke Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. The Manufacturers Life Insurance Company raised its position in shares of Stoke Therapeutics by 16.7% in the second quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock valued at $189,000 after purchasing an additional 1,994 shares during the period. Quest Partners LLC bought a new stake in Stoke Therapeutics during the 2nd quarter valued at $29,000. Los Angeles Capital Management LLC lifted its position in shares of Stoke Therapeutics by 7.2% during the second quarter. Los Angeles Capital Management LLC now owns 66,765 shares of the company’s stock worth $902,000 after acquiring an additional 4,508 shares in the last quarter. Rhumbline Advisers boosted its holdings in shares of Stoke Therapeutics by 14.3% in the second quarter. Rhumbline Advisers now owns 47,860 shares of the company’s stock worth $647,000 after acquiring an additional 5,990 shares during the period. Finally, Intech Investment Management LLC purchased a new position in shares of Stoke Therapeutics in the third quarter valued at $160,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.